Zeynep Ülkü GÜN, Ömer Faruk BAHÇECİOĞLU, Selim GÖK

Linezolid drug interactions: A retrospective study

Linezolid is an antimicrobial drug which has good activity against clinically important gram-positive methicillin and vancomycin resistant microorganisms. However, linezolid is a lifesaving medicine for resistant infections, it can be responsible for severe drug interactions. Linezolid is a nonselective, weak, reversible inhibitor of monoamine oxidase A and B. That is why it can lead to increase activity of concomitant administrated monoamine oxidase inhibitors, serotonergic and adrenergic agents. This study is a one-month retrospective chart review of inpatients at a university hospital. All charts in a 1368 bed university hospital were reviewed via electronic records. Charts, which include linezolid have evaluated by clinical pharmacists and were assessed for prevalence and severity of potential drug-drug interactions using the Up- ToDate drug reference database. Fifty-four patients included in this study. Total number of interactions with linezolid was 86, which was 28.2 percent of all interactions. Eight of these interactions were in X category (avoid combination), 59 were in D category (consider therapy modification) and 19 were in C category (monitor therapy). There wasn’t any interaction classified as category B (no action needed). In our study, it was predicted that serotonergic toxicity and hypertension may develop in many patients due to concurrent administration of linezolid with serotonergic and/or adrenergic drugs. If the coadministration of these drugs is unavoidable, physicians should be alert to the symptoms and management of serotonergic toxicity and hypertension. The number of patients and its retrospective nature were limiting factors of our study. More comprehensive prospective studies are needed.

PDF

___

1. Louhichi S, Neffati A, Hajjej Z, et al. Proper use of antibiotics: situation of linezolid at the intensive care unit of the Tunisian Military Hospital. Pan African Med J. 2011;25:1-7

2. Hashemian SM, Farhadi T, Ganjparvar M. Linezolid:a review of its properties, function and use in critical care. Drug Design, Development Therapy. 2018;12:1759-67

3. Ramsey TD, Lau TTY, Ensom MHH et al. Serotonergic and adrenergic drug interactions associated with linezolid: A critical review and practical management approach. Ann Pharmacotherapy. 2013;47:543-60.

4. https://www.uptodate.com/drug-interactions/?source=responsive_home#didruglist access date 12.06.2019

5. Quinn QK, Stern TA. Linezolid and serotonin syndrome. Prim Care Companion J Clin Psychiatry. 2009;11:353-6

6. Woytowish MR, Maynor LM. Clinical relevance of linezolid-associated serotonin toxicity. The Annals of Pharmacotherapy. 2013;47:388-97

7. Dai D, Fenstein JA, Morrison W, et al. Epidemiology of polypharmacy and potential drug-drug interactions among pediatric patients in intensive care units in U.S. chidren’s hospitals. Pediatr Crit Care Med. 2016;17(5):218-28

8. Kuscu F, Ulu A, Inal AS, et al. Potential drug-drug interactions with antimicrobials in hospitalized patients: a multicenter point-prevelance study. Med Sci Monit. 2018;24:4240-7.